# A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability

> **NCT01958047** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 64 (actual)

## Conditions studied

- Pharmacokinetics
- Pharmacodynamics
- Healthy Subjects
- Effect of Race

## Interventions

- **DRUG:** ASP3652

## Key facts

- **NCT ID:** NCT01958047
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958047, "A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01958047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*